Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/26510

Title: Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
Authors: Van Praet, Charles
Rottey, Sylvie
Van Hende, Fransien
Pelgrims, Gino
Demey, Wim
Van Aelst, Filip
Wynendaele, Wim
Gil, Thierry
Schatteman, Peter
Filleul, Bertrand
Schallier, Dennis
Machiels, Jean-Pascal
Schrijvers, Dirk
Everaert, Els
D'Hondt, Lionel
Werbrouck, Patrick
Vermeij, Joanna
Mebis, Jeroen
Clausse, Marylene
Rasschaert, Marika
Van Erps, Joanna
Verheezen, Jolanda
Van Haverbeke, Jan
Goeminne, Jean-Charles
Lumen, Nicolaas
Issue Date: 2016
Abstract: Background: Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The current study assesses efficacy and safety of AA in mCRPC patients previously treated with docetaxel who started treatment during the Belgian compassionate use program (January 2011 July 2012). Patients and methods: Records from 368 patients with mCRPC from 23 different Belgian hospitals who started AA 1000 mg per day with 10 mg prednisone or equivalent were retrospectively reviewed (September 2013 December 2014). Prostate-specific antigen (PSA) response (decrease >= 50%), time to PSA progression (increase >50% over PSA nadir in case of PSA response/ >25% in absence of PSA response), time to radiographic progression (on bone scans or for soft tissue lesions using Response Evaluation Criteria In Solid Tumors 1.1), overall survival and adverse event rate (Common Terminology Criteria for Adverse Events v4.03) were analyzed. Kaplan-Meier statistics were applied. Results: Overall, 92 patients (25%) had an Eastern Cooperative Oncology Group performance status >= 2. Median age was 73 years, median PSA was 103 ng/dl. PSA response was observed in 131 patients (37.4%). Median time to PSA and radiographic progression was 4.1 months (95% CI: 3.6 /1.6) and 5.8 months (5.3-6.4), respectively. Median overall survival was 15.1 months (13.6-16.6). Most common grade 3 to 4 adverse events were anemia (13.9%), hypokalemia (7.3%), fatigue (6.8%), and pain (6.3%). Median duration of AA treatment was 5.3 months (interquartile range: 2.8-10.3). The main study limitation is its retrospective design. Conclusions: These real-world data on post-docetaxel AA efficacy are in line with the COU-AA-301 trial. Importantly, incidence of severe anemia and hypokalemia is up to 50% higher than reported in previous studies. (c) 2016 Elsevier Inc. All rights reserved.
URI: http://hdl.handle.net/1942/26510
Link to publication: https://dial.uclouvain.be/pr/boreal/object/boreal%3A172061/datastream/PDF_01/view
DOI: 10.1016/j.urolonc.2015.12.017
ISI #: 000376520300003
ISSN: 1078-1439
Category: A1
Type: Journal Contribution
Appears in Collections: Research publications

Files in This Item:

Description SizeFormat
Published version607.65 kBAdobe PDF

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.